Gland Pharma Overview
- Year Founded
-
1978

- Status
-
Public
- Employees
-
4,217

- Stock Symbol
-
GLAND

- Investments
-
2
- Share Price
-
$17.20
- (As of Friday Closing)
Gland Pharma General Information
Description
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.
Contact Information
Website
www.glandpharma.comCorporate Office
- Survey Number 143-148, 150 & 151 Near Gandimaisamma 'X' Roads
- D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District
- Hyderabad, 500043
- India
Corporate Office
- Survey Number 143-148, 150 & 151 Near Gandimaisamma 'X' Roads
- D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District
- Hyderabad, 500043
- India
Gland Pharma Stock Performance
As of 16-May-2025, Gland Pharma’s stock price is $17.20. Its current market cap is $2.83B with 165M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$17.20 | $17.08 | $14.94 - $26.44 | $2.83B | 165M | 320K | $0.51 |
Gland Pharma Financials Summary
As of 31-Dec-2024, Gland Pharma has a trailing 12-month revenue of $682M.
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
---|---|---|---|---|
EV | 3,106,173 | 3,421,987 | 2,128,317 | 6,686,830 |
Revenue | 681,919 | 681,485 | 447,317 | 588,416 |
EBITDA | 159,755 | 162,865 | 128,047 | 213,885 |
Net Income | 84,182 | 93,308 | 97,268 | 162,623 |
Total Assets | 1,278,426 | 1,069,114 | 1,033,074 | |
Total Debt | 0 | 44,628 | 542 | 625 |
Gland Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Gland Pharma Comparisons
Industry
Financing
Details
Gland Pharma Competitors (7)
One of Gland Pharma’s 7 competitors is Cipla, a Corporation company based in Mumbai, India.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cipla | Corporation | Mumbai, India | ||||
Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
Emcure Pharmaceuticals | Formerly PE-Backed | Pune, India | ||||
Natco Pharma | Corporation | Hyderabad, India | ||||
Mankind Pharma | Formerly PE-Backed | New Delhi, India |
Gland Pharma Patents
Gland Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20190295732-A1 | Apparatus for predicting outbreak of avian influenza | Inactive | 21-Mar-2018 | ||
US-20180079669-A1 | Method for selection of appropriate location to reduce the atmospheric carbon dioxide through large-scale iron fertilization with less accumulation rate of volcanic sulfur compounds | Inactive | 23-Jul-2015 |
Gland Pharma Signals
Gland Pharma Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Gland Pharma Investments & Acquisitions (2)
Gland Pharma’s most recent deal was a Merger/Acquisition with Cenexi for . The deal was made on 27-Apr-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Cenexi | 27-Apr-2023 | Merger/Acquisition | Pharmaceuticals | ||
Vitane Biologics (Equipment and Facility) | 19-May-2021 | Corporate Asset Purchase | Buildings and Property |
Gland Pharma ESG
Risk Overview
Risk Rating
Updated March, 02, 2024
27.25 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile

Pharmaceuticals
Industry
of 843
Rank
Percentile

Pharmaceuticals
Subindustry
of 419
Rank
Percentile

Gland Pharma Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Cenexi | Fontenay-Sous-Bois, France | 2004 |
Gland Pharma FAQs
-
When was Gland Pharma founded?
Gland Pharma was founded in 1978.
-
Where is Gland Pharma headquartered?
Gland Pharma is headquartered in Hyderabad, India.
-
What is the size of Gland Pharma?
Gland Pharma has 4,217 total employees.
-
What industry is Gland Pharma in?
Gland Pharma’s primary industry is Pharmaceuticals.
-
Is Gland Pharma a private or public company?
Gland Pharma is a Public company.
-
What is Gland Pharma’s stock symbol?
The ticker symbol for Gland Pharma is GLAND.
-
What is the current stock price of Gland Pharma?
As of 16-May-2025 the stock price of Gland Pharma is $17.20.
-
What is the current market cap of Gland Pharma?
The current market capitalization of Gland Pharma is $2.83B.
-
What is Gland Pharma’s current revenue?
The trailing twelve month revenue for Gland Pharma is $682M.
-
Who are Gland Pharma’s competitors?
Cipla, Glenmark Pharmaceuticals, Emcure Pharmaceuticals, Natco Pharma, and Mankind Pharma are some of the 7 competitors of Gland Pharma.
-
What is Gland Pharma’s annual earnings per share (EPS)?
Gland Pharma’s EPS for 12 months was $0.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »